Pusztai L - Search Results

1

Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226.

Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, Dakhil SR, Tirumali NR, Gralow JR, Hortobagyi GN, Pusztai L, Mehta RS, Hayes DF, Kidwell KM, Henry NL, Barlow WE, Rae JM, Hertz DL. Rutherford DV, et al. Among authors: pusztai l. Pharmacogenomics. 2023 Aug;24(12):665-673. doi: 10.2217/pgs-2023-0097. Epub 2023 Aug 24. Pharmacogenomics. 2023. PMID: 37615099

2

Discouraging news for high-dose chemotherapy in high-risk breast cancer.

Pusztai L, Hortobagyi GN. Pusztai L, et al. Lancet. 1998 Aug 15;352(9127):501-2. doi: 10.1016/S0140-6736(05)79310-7. Lancet. 1998. PMID: 9716049 No abstract available.

3

Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.

Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Pusztai L, et al. Am J Clin Oncol. 1998 Oct;21(5):442-6. doi: 10.1097/00000421-199810000-00004. Am J Clin Oncol. 1998. PMID: 9781596 Clinical Trial.

4

Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.

Pusztai L, Holmes FA, Fraschini G, Hortobagyi GN. Pusztai L, et al. Cancer Chemother Pharmacol. 1999;43(1):86-91. doi: 10.1007/s002800050867. Cancer Chemother Pharmacol. 1999. PMID: 9923546 Clinical Trial.

5

Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer.

Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Pusztai L, et al. Breast Cancer Res Treat. 1999 May;55(1):1-8. doi: 10.1023/a:1006161906667. Breast Cancer Res Treat. 1999. PMID: 10472774

6

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

7

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.

Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2001 Sep-Oct;7(5):413-20. Cancer J. 2001. PMID: 11693900

8

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. Among authors: pusztai l. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

9

Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.

Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2002 Nov-Dec;8(6):461-8. doi: 10.1097/00130404-200211000-00010. Cancer J. 2002. PMID: 12500855

10

Estrogen receptors and distinct patterns of breast cancer relapse.

Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Hess KR, et al. Among authors: pusztai l. Breast Cancer Res Treat. 2003 Mar;78(1):105-18. doi: 10.1023/a:1022166517963. Breast Cancer Res Treat. 2003. PMID: 12611463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

551 results

Search Page